Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Temafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | HPGD | P15428 | 8/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.61 |
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TOP2A | P11388 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temafloxacin SCHEMBL29414891 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL20769825 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| (S)-Temafloxacin SCHEMBL48096 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL48095 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL134293 | 0.99 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL9667105 | 0.99 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL2637551 | 0.99 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| (S)-Temafloxacin SCHEMBL193405 | 0.99 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| (S)-Temafloxacin SCHEMBL9667109 | 0.99 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL313347 | 0.98 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-3684373-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | Atopic Medical, LLC (US) | 2020-07-29 | — | — | EP | claimed |
| WO-2019060553-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | Atopic Medical, LLC (US) | 2019-03-28 | — | — | WO | claimed |
| US-20190083518-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL, INC. | 2019-03-21 | — | — | US | claimed |
| EP-2413974-B1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RES & DEV FOUNDATION (IL) | 2016-03-23 | — | — | EP | claimed |
| US-9149536-B2 | Conjugated antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2015-10-06 | — | — | US | claimed |
| US-20140357591-A1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2014-12-04 | — | — | US | claimed |
| US-8809286-B2 | Conjugated antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2014-08-19 | — | — | US | claimed |
| EP-2413974-A1 | CONJUGATED ANTIMICROBIAL AGENTS | Technion Research & Development Foundation Ltd. (IL) | 2012-02-08 | — | — | EP | claimed |
| US-20120018334-A1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2012-01-26 | — | — | US | claimed |
| WO-2010113151-A1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-10-07 | — | — | WO | claimed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-12589157-B1 | Compositions of drug delivery agents and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| WO-2008157205-A2 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1778252-A2 | NONCARDIOTOXIC PHARMACEUTICAL COMPOUNDS | Barbeau, Donald L. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020573-A2 | NONCARDIOTOXIC PHARMACEUTICAL COMPOUNDS | BARBEAU DONALD L (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | B&G PARTNERS, LLC | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | KCNN3, TNNI3, TNNT2 | ALDH1A1 1667/4885KDM4E 3018/4885HPGD 1801/4885 |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | ALDH1A1 4294/4885KDM4E 4014/4885HPGD 1183/4885 |
| US-12589157-B1 | Compositions of drug delivery agents and methods of use thereof | CALR, ABCC1, CALU | ALDH1A1 3670/4885KDM4E 1861/4885HPGD 2630/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | ALDH1A1 3617/4885KDM4E 1239/4885HPGD 1921/4885 |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | ALDH1A1 1287/4885KDM4E 3174/4885HPGD 324/4885 |
| US-20140357591-A1 | CONJUGATED ANTIMICROBIAL AGENTS | OGT, IMMT, DNTT | ALDH1A1 1888/4885KDM4E 3478/4885HPGD 3590/4885 |
| US-20120018334-A1 | CONJUGATED ANTIMICROBIAL AGENTS | OGT, IMMT, DNTT | ALDH1A1 1888/4885KDM4E 3478/4885HPGD 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.